GSC
PRQR icon

Ground Swell Capital’s ProQR Therapeutics PRQR Stock Holding History

Ground Swell Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21,640
Closed -$17K – 173
2022
Q2 		$17K Buy
+21,640
New +$16.1K 0.03% 118

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ground Swell Capital's PRQR Position: Q3 2022 in Review

Ground Swell Capital sold out of ProQR Therapeutics (PRQR) in Q3 2022, closing a stake of 21,640 shares — an estimated $17K sold.

Ground Swell Capital first reported a position in PRQR in Q2 2022 and held it in 1 quarter. The position peaked at $17K in Q2 2022. 47 funds tracked by Wall St. Rank hold PRQR as of Q3 2022.

  • Ground Swell Capital reported no remaining ProQR Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ground Swell Capital sold 21,640 ProQR Therapeutics shares in Q3 2022, an estimated $17K.
  • Ground Swell Capital first reported a position in ProQR Therapeutics in Q2 2022 and held it in 1 quarter.
  • Ground Swell Capital's ProQR Therapeutics position peaked at $17K in Q2 2022.
  • 47 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2022.

Based on Ground Swell Capital's 13F filing for Q3 2022, filed 14 Nov 2022.